- For patients with primary plasma cell leukemia (pPCL), outcomes may be optimized through upfront autologous stem cell transplantation (ASCT) and novel approaches including proteasome inhibitors and immunomodulators.
Why this matters
- Data are limited regarding clinical characteristics and outcomes in patients with PCL.
- Multicenter study to investigate clinical characteristics, outcomes, and prognostic factors in 117 patients with pPCL.
- Median age: 61 years (range, 27-85 years).
- Funding: None disclosed.
- 50 months (95% CI, 33-76 months) median follow-up.
- 78% overall response rate.
- 21% complete response, 22% very good partial response, 36% partial response, and 22% no response.
- 35 months (95% CI, 24.3-46 months) median OS in patients who received upfront ASCT vs 13 months (95% CI, 6.3-35.8 months) in patients who did not (Log-rank P<.001>
- 3 independent predictors of inferior survival were identified in multivariate analyses: age ≥60 years, platelet count ≤100×109/L, and peripheral blood plasma cell count ≥20×109/L.
- 46 months (95% CI, 33-not reached) median OS in patients with no independent predictors, 27 months (95% CI, 14-41 months) with 1 independent predictor, and 12 months with 2-3 independent predictors (95% CI, 6-20 months).
- Retrospective data.